Upon completion of this course, a participant should be able to:

• Review the epidemiology of hepatitis C virus (HCV) in the United States and new approaches to increase its diagnosis.
• Discuss strategies to simplify HCV treatment.
• Highlight challenges and unresolved questions to achieve HCV elimination in the United States.

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this other (live and enduring) activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: October 8, 2024 Expiration Date: October 8, 2025

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

Nathan Furukawa,MD, MPH:
Nothing to Disclose

Ponni Perumalswami, MD, FAASLD:
Nothing to Disclose

Jennifer Price, MD, PhD:

Research Grants:  AbbVie, VIR, Zydus, Gilead, Merck & Co., Inc.
Intellectual Property Rights: AbbVie, Bristol Myers-Squibb, Johnson & Johnson, Merck & Co., Inc.

Harrys Torres, MD, FACP, FIDSA, FAASLD:

Research Grants: Gilead Sciences, Merck & Co., Inc, National Cancer Institute

Faculty Biographies: 

Nathan Furukawa, MD, MPH:

Dr. Furukawa is the Senior Advisor for Hepatitis C Elimination in the Division of Viral Hepatitis and works to develop the strategies, programs, and partnerships necessary to advance the elimination of hepatis C. He served as the CDC focal point for the acceleration of FDA authorization of Cepheid’s Xpert HCV point-of-care HCV RNA test in collaboration with the NIH Independent Test Assessment Program (ITAP). He is currently guiding the development and implementation of strategies supporting the adoption of point-of-care testing in the United States.

Ponni Perumalswami, MD, FAASLD:

Dr. Ponni Perumalswami is an associate professor of medicine at University of Michigan and Director of the Liver Clinic at the Ann Arbor VA Healthcare System. She is a health services researcher focused on improving access to care for patients with liver disease. Her research focuses on the development of integrated care models to improve viral hepatitis and alcohol-associated liver care within underserved and vulnerable communities. She has directed a community health worker lead model of viral hepatitis and liver cancer outreach for West African in New York City and is now adapting the model to Asian American communities in Michigan. In 2020, Perumalswami joined the steering committee of the Michigan Department of Health and Human Services’ Hepatitis C Virus Elimination Plan and is co-leader of the We Treat Hep C Initiative in Michigan. She also works with the Michigan Opioid Collaborative on outreach and training initiatives aimed at increasing hepatitis C screening and treatment by primary care providers in rural areas of the state.

Jennifer Price, MD, PhD:

Dr. Price is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and Director of the UCSF Viral Hepatitis Center. Her research examines the contributions of novel and traditional factors associated with liver disease and fibrosis progression in large observational HIV cohorts, with or without viral hepatitis. Dr. Price is a PI of the San Francisco Bay Area site of the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS), which integrates two of the largest and longest running NIH-funded prospective cohorts of men and women with and at risk for HIV in the U.S. She also serves as co-Chair of the MWCCS Liver Working Group and Vice Chair of the AASLD HCV SIG. Dr. Price is a member of the End Hep C SF Coordinating Committee and leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She is the founding director of the DeLIVER Care Van, a mobile unit aimed at improving access to HCV screening and high-quality liver-related health care among marginalized communities.

Harrys Torres, MD, FACP, FIDSA, FAASLD:

Dr. Torres is an Ashbel Smith Distinguished Professor, and Professor of Medicine in the Department of Infectious Diseases, Infection Control, and Employee Health and an Adjunct Professor in the Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine, and infectious disease, with additional accreditations in HIV/AIDS and Tropical Medicine and Hygiene. He is a co-author of almost 140 articles published in peer-reviewed journals. His work on viral hepatitis has received multiple awards from the AASLD and the American Society of Clinical Oncology, among others. Toolbox Manage Features Settings Life Cycle Preview Clone Course Keywords/Tags Metadata Navigations Admin Notes (0) Advanced Tools Documentations (0)